Polly Matzinger has worked as a bartender, carpenter, jazz musician, playboy bunny, and dog trainer. She is currently chief of the ghost lab and the section on T-Cell Tolerance and Memory. She worried for years that the dominant model of immunity does not explain a wealth of accumulated data and suggested an alternative, the Danger model, which suggests that the immune system is far less concerned with things that are foreign than with those that do damage. This model, whose two major tenets were conceived in a bath and on a field while herding sheep, has very few assumptions and yet explains most of what the immune system seems to do right, as well as most of what it appears to do wrong, covering such areas as transplantation, autoimmunity, and the immunobiology of tumors. The model has been the subject of a BBC “horizon” film and was featured in three other films about immunity, as well as countless articles in both the scientific and the lay press. In 2013, her section was assigned to the Laboratory of Immunogenetics.
Matzinger’s website: https://www.niaid.nih.gov/research/polly-matzinger-phd
Peter Bretscher is interested in how immune responses are regulated to result in self-nonself discrimination and immune class regulation. In more recent decades he has been interested in applying basic understanding to achieve effective vaccination against and treatment of infectious diseases and cancers. He studied physics at Cambridge University, UK, and obtained his PhD (1968) in protein crystallography, also at Cambridge. During his graduate studies he became interested in immunology, and so changed his field of research. He is now a Professor at the University of Saskatchewan, Canada. He has recently authored two books, Rediscovering the Immune System as an Integrated Organ and The Foundations of Immunology and Their Pertinence to Medicine.
Bretscher’s website: https://medicine.usask.ca/profiles/microbiology-and-immunology/peter-bretscher.php#ResearchAreas
Colin Anderson completed a Ph.D. degree at the University of Western Ontario (London Ontario) in the field of immunology and then post-doctoral training at the Institut Curie in Paris France and the National Institutes of Health in Bethesda Maryland. He is currently a full Professor in the Departments of Surgery and Medical Microbiology & Immunology at the University of Alberta and Director of the Division of Surgical Research. He is also a scientist of the Alberta Diabetes Institute (http://adi.ualberta.ca/en/ResearchMembers.aspx) and the Alberta Transplant Institute. His group’s research is in the interrelated areas of transplantation immunology, diabetes, multiple sclerosis and immune tolerance.
Zlatko Dembic is a professor of immunology, cell biology and microbiology at the University of Oslo. He studied medicine at the University of Rijeka, Croatia and obtained his MD in 1977. He later also obtained a PhD at the same University on the work done at the Basel Institute for Immunology (BII), Switzerland (1984-1986). Before his PhD thesis, he worked at the Department of Physiology, Medical Faculty, University of Zagreb, Croatia (1977-1982), and Max-Planck-Institute for Biology (Immunogenetics) in Tübingen, Germany (1982-1984). After BII he went to work at Hoffman-La Roche in Basel for several years (1986 -1995). Then, he joined the Institute for Immunology and Rheumatology (IGRI, Oslo, Norway) in 1995. He worked at IGRI and later at the Institute of Immunology (Oslo University Hospital Rikshospitalet, Oslo, Norway) until 2002, when he got his current post at the Department of Oral Biology, Faculty of Dentistry, adjacent to Rikshospitalet. He is the Head of the Molecular Genetics Lab and investigates molecular landscape of cancer from immunologic perspective. He was the President of the Norwegian Society for Immunology (2008-2010), and is currently Associate editor of Scandinavian Journal of Immunology.
Zlatko Dembic’s website: http://folk.uio.no/zlatkod/index.html and https://www.odont.uio.no/iob/personer/vit/zlatkod/index.html
Bjarne Bogen is a professor of immunology at the University of Oslo. He is an MD from the University of Oslo and obtained a PhD from the University of Tromsø. He has enjoyed sabbaticals at a number of institutions including Basel Institute for Immunology and Stanford University. He is currently director of the KG Jebsen Centre for influenza vaccine research. His research interests are T-B cell collaboration, tumor immunology and vaccine development.
Bogen lab’s website: http://www.med.uio.no/klinmed/english/people/aca/bbogen/
Ludvig M. Sollid is Professor and Director of the Centre for Immune Regulation (a Research Council of Norway and Federation of Clinical Immunology Societies center of excellence) and the KG Jebsen Coeliac Disease Research Centre, both located in Oslo. He has a research interest in the genetic basis and disease mechanisms of autoimmune disorders. His group is currently working on the characterization of the antigen receptors of T cells and B cells that recognize disease relevant antigens in celiac disease.
Sollid lab’s website: https://www.med.uio.no/cir/english/research/groups/sollid/
Inger Øynebråten studied biology at UiT The Arctic University of Norway and obtained a PhD at University of Oslo, Norway. She is Deputy group leader of the Tumor Immunology Lab (http://ous-research.no/corthay) at the Dept. of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway. Research activities and interests include mechanisms for activation of immune cells, intracellular trafficking, and vaccine design.
Einar Martin Aandahl
Marit Inngjerdingen is heading the Lymphocyte activation group at the Department of Immunology, Oslo University Hospital. Her group studies how cancer cells evade the immune system, with a focus on the interplay between NK cells and acute leukemia, and how NK cells may be manipulated to eradicate resistant cancer cells. She obtained a PhD in immunology at the University of Oslo in 2001, followed by a post doc at UCSF, San Francisco, and worked thereafter as post doc and researcher at Oslo University Hospital.
Inngjerndingen lab’s website: http://ous-research.no/inngjerdingen
Alexandre Corthay is a specialist in cancer immunology. He studied biology at the University of Geneva, Switzerland and obtained a PhD at Lund University, Sweden. He is the Head of the Tumor Immunology lab at the Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway. He investigates how the immune system fights cancer in mice and humans with a main focus on two types of immune cells, namely T cells and macrophages. He is currently the President of the Norwegian Society for Immunology.
Corthay lab’s website: http://ous-research.no/corthay
Olav Sundnes is a dermatology resident at Rikshospitalet, Oslo University Hospital. He received his medical degree from Royal College of Surgeons in Ireland. In 2017 he obtained a PhD in immunology from Oslo University, based on research performed in the group of Guttorm Haraldsen at Department of Pathology, Oslo University Hospital. His main research interests are interleukin-33, keratinocyte biology and atopic dermatitis.
Per H. Nilsson is working on innate immunity with the focus on the biology of the complement system. He has his master degree in biomedicine and obtained his PhD at the Linnaeus University, Kalmar, Sweden in 2012, on the interaction between the complement system and platelets. He is researcher in the group of Tom Erik Mollnes at the Department of Immunology, University of Oslo. He is working on the combined inhibition of complement and CD14 as treatment regimen to attenuate the inflammatory response in disease.
Søren Pischke is a specialist in anaesthesiology and intensive care with research focus on innate immunity during sterile inflammation. He studied medicine at the University of Freiburg, Germany. He obtained a PhD at University of Oslo, Norway and has international research experience from stays in Germany and USA. He is senior consultant at the intensive care unit at Oslo university hospital, Rikshospitalet. He investigates how the innate immune system, namely the complement system and toll-like receptors, mediate sterile inflammation in the course of e.g. ischemia/reperfusion injury and how to therapeutically approach these events. He is currently board member of the Scandinavian Society for Anesthesiology and Intensive care medicine.